SPID ® -Technology utilizes compartmentalization to enable sequential release of carbidopa and levodopa, offering a potential new approach for drug delivery in Parkinson’s disease treatment. NEW YORK--( BUSINESS WIRE )--Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced the publication of a new study in the Journal Pharmaceutics (MDPI) that highlights the effectiveness of its propriet

NEW YORK--( BUSINESS WIRE )--Laxxon Medical, a leading pharmaceutical technology company, pioneering a new generation of advanced oral drug delivery systems, today announced that it will be attending BIO-Europe 2025 and the Jefferies Healthcare Conference, two of the world’s premier partnering events for the Life Sciences industry. “These two conferences are excellent opportunities to engage with forward-thinking leaders and companies seeking innovative solutions to advance d

NEW YORK--( BUSINESS WIRE )--Laxxon Medical Corp., a leading pharmaceutical technology company pioneering a new generation of advanced...

Laxxon has received a grant by Freistaat Thüringen and the ESF Plus (European Social Fund) for the further development of LXM.2.

Laxxon's New Generation Levodopa/Carbidopa for Parkinson's Disease project, LXM.5, has been awarded a grant.

[New York, New York] – Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced drug delivery...

[New York, New York] – Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug...

NEW YORK, NY / ACCESSWIRE / January 7, 2024 /  Laxxon Medical, a leading pharma-technology company pioneering a new generation of...

Laxxon is seeking out-licensing opportunities for lead asset LXM.2, or co-developments projects with 3DSP platform technology SPID® at...

The cooperation between Laxxon and Adare enables the clinical and commercial production of advanced drug delivery systems at Adare’s cGMP fa

Counterfeit medicine is a threat to public health. Technologies like 3D printing and QR codes help protect both patients and drug integrity.

Learn all about GLP-1 medications for diabetes and obesity, including benefits, side effects, and how they work.

Explore the future of drug delivery, Laxxon Medical's innovative 3D technology, and how controlled-release drugs are reshaping healthcare.

Laxxon's extended-release Levodopa is revolutionizing Parkinson's treatment, increasing patient quality of life with improved medication.

3D screen printing could revolutionize the fight against counterfeit medication, innovating anti-counterfeiting measures for patient safety.

Learn how Laxxon Medical's 3D screen printing and QR codes combat counterfeit medicine. Discover the impact on safety and global healthcare.

Delve into the complexities of obesity, from its global impact to the physical, mental, and social effects, and various treatment options.

Discover the world of diabetes, from causes to treatments. Explore the latest research and advancements in managing this complex disease.

Explore the delicate balance between pharmaceutical patent extensions and patient access in healthcare and it's role in driving innovation.

Discover how technology like Generative AI, IoMT, and 3D Printing is accelerating pharma research, enhancing speed, efficiency and accuracy.